Skip to main content
. 2018 Jun 28;119(3):339–346. doi: 10.1038/s41416-018-0167-x

Fig. 2.

Fig. 2

Association between changes in LDH or S100B after the first two cycles of immunotherapy and tumour response in the (a and c) pembrolizumab cohort, and in the (b and d) ipilimumab + nivolumab cohort. CR complete response, LDH lactate dehydrogenase, P P-value, PD progressive disease, PR partial response, SD stable disease